Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents

Peizeng Yang*, Zi Ye, Liping Du, Qingyun Zhou, Jian Qi, Liang Liang, Lili Wu, Chaokui Wang, Aize Kijlstra

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Web of Science)

Abstract

Purpose: To investigate the effectiveness, visual outcome, and prognostic factors of Vogt-Koyanagi-Harada (VKH) disease treatment with a reduced dose of corticosteroids combined with immunosuppressive agents. Methods: The clinical characteristics, auxiliary examinations, treatment result, visual outcome, and prognostic factors in VKH patients were analyzed. Results: A total of 998 VKH patients were divided into posterior uveitis group (Group1), anterior uveal involvement group (Group 2), and recurrent granulomatous anterior uveitis group (Group 3). Reduced doses of corticosteroids combined with immunosuppressive agents were used for 1-1.5 years. Uveitis was controlled in 100%, 100%, and 96.8% of these three groups, respectively. Visual improvement and stability was observed in 98.1%, 96.5%, and 88.3%, respectively. Treatment after disease onset, visual acuity at first visit, and 1 month after treatment was positively associated with BCVA at last visit (p < 0.05). Conclusion: A reduced dose of corticosteroids combined with immunosuppressive agents effectively controlled the intraocular inflammation and improved visual acuity in most Chinese VKH patients.
Original languageEnglish
Pages (from-to)254-261
Number of pages8
JournalCurrent Eye Research
Volume43
Issue number2
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • VKH disease
  • Treatment regimen
  • Prognosis factor
  • SUNSET GLOW FUNDUS
  • PROGNOSTIC-FACTORS
  • CHINESE PATIENTS
  • INFLAMMATION
  • RECURRENCE
  • DIAGNOSIS
  • SINGAPORE
  • SPECTRUM
  • OUTCOMES
  • THERAPY

Cite this